Current Problems in Cancer最新文献

{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(25)00019-4","DOIUrl":"10.1016/S0147-0272(25)00019-4","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101192"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the clinical efficacy of neoadjuvant intravesical Mitomycin C in naïve non-muscle invasive urinary bladder cancer: A systematic review and meta-analysis","authors":"Anuja Thakur ,&nbsp;Lalit Kumar ,&nbsp;Sakshi Agarwal ,&nbsp;Rachana Tripathy ,&nbsp;Yashasvi Singh ,&nbsp;Sameer Trivedi ,&nbsp;Ujwal Kumar","doi":"10.1016/j.currproblcancer.2025.101198","DOIUrl":"10.1016/j.currproblcancer.2025.101198","url":null,"abstract":"<div><h3>Background and Objective</h3><div>Naïve non-muscle invasive bladder cancer (NMIBC) is commonly treated with transurethral resection (TURBT), but recurrence and progression remain concerns.</div><div>This meta-analysis, the first we have conducted on this topic, compared recurrence and progression rates between patients treated with neoadjuvant Mitomycin C (MMC) and the control group (TURBT alone).</div></div><div><h3>Methods</h3><div>Relevant articles were identified and appraised through a structured literature assessment. Databases searched included PubMed, Medline, Scopus, and Science Direct. Duplicate publications, book sections, conference papers, encyclopedias, case reports, magazine articles, presentations, theses, protocols, systematic reviews, and meta-analyses were excluded. Heterogeneity was assessed using the I².</div></div><div><h3>Key findings and limitations</h3><div>The meta-analysis evaluated recurrence rates, progression rates, and adverse events. No heterogeneity was observed (I²=0 %). The pooled odd ratio (OR) for recurrence was 2.554 (95 % CI: 1.637-3.986), indicating a significant decrease in recurrence for the MMC group (<em>P</em> &lt; 0.001). For progression rates, the overall pooled OR was 1.508 (95 % CI: 0.832-2.734), suggesting that the MMC group showed a lower progression rate. However, this difference was not statistically significant (<em>P</em> = 0.176).Adverse events varied, with the MMC group showing fewer cases of hematuria (8.4 % vs. 34 %) but more irritative bladder symptoms.</div></div><div><h3>Conclusions and Clinical Implications</h3><div>The meta-analysis suggests lower recurrence and progression rates in the neoadjuvant MMC group compared to the control group. Both groups experienced a comparable range of adverse events, suggesting that both treatment approaches exhibit a similar safety profile. Larger and more randomized controlled trials (RCT) are needed to confirm MMC's effectiveness in NIMBC treatment and establish its role in clinical practice.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101198"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of gene therapy approaches for malignant gliomas: A systematic review and meta-analysis","authors":"Elnaz Amanzadeh Jajin,&nbsp;Saeed Oraee-Yazdani,&nbsp;Alireza Zali,&nbsp;Roozbeh Tavanaei","doi":"10.1016/j.currproblcancer.2025.101183","DOIUrl":"10.1016/j.currproblcancer.2025.101183","url":null,"abstract":"<div><h3>Background</h3><div>Malignant gliomas are the most aggressive brain tumors with no certain therapeutic methods. Nowadays, novel treatment methods are introduced for gliomas among which gene therapy is known as a promising and robust method. In this method, genes with key roles in the prevention of cell cycle or induction of cell suicide are transferred to the tumor site using vectors. Viral vectors are the most popular transfer methods, while the liposomes are also used for gene therapy.</div></div><div><h3>Methods</h3><div>This meta-analysis and systematic review was performed based on PRISMA guidelines. We performed a comprehensive search in databases including PubMed, Embase, and clinicaltrial.gov. After processing and filtering the articles, phase 1 clinical trials were chosen for the evaluation of the efficacy and safety of gene therapy for malignant gliomas.</div></div><div><h3>Results</h3><div>The obtained results showed that gene therapy increases overall survival (OS) and progression-free survival (PFS) in two years of follow-up. Subgroup analysis also showed that cytokines exhibit the highest effectiveness compared to suicide genes and oncolytic genes. It was found that gene therapy is more efficient for recurrent gliomas than primary gliomas. The subgroup analysis for vectors revealed that Adenovirus is the most effective for increasing the OS in malignant glioma patients.</div></div><div><h3>Conclusion</h3><div>Gene therapy is an immunotherapy method for malignant gliomas following the standard treatment approach. Considering the effectiveness of gene therapy on the survival of patients, it is hoped that solving related issues with gene therapy will help to increase the OS rate in this malignant disease.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101183"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas","authors":"Avaniyapuram Kannan Murugan ,&nbsp;Siddarth Kannan ,&nbsp;Ali S. Alzahrani","doi":"10.1016/j.currproblcancer.2025.101182","DOIUrl":"10.1016/j.currproblcancer.2025.101182","url":null,"abstract":"<div><div>Programmed cell death protein 1 (<em>PDCD1</em>) and cluster of differentiation 274 (<em>CD274</em>) expression is implicated in escaping tumors from immune surveillance. Immune checkpoint inhibitors show promise in cancer therapy, yet their efficacy in glioblastomas, particularly with <em>IDH1</em> mutations, remains unclear. This study analyzed two independent NGS datasets (n = 577 and n = 153) from TCGA to investigate the expression of <em>PDCD1</em> and <em>CD274</em> in glioblastomas and their relationship with <em>IDH1</em> mutations. We used cBioPortal for mutation analysis, RNA seq for expression analysis, miRDB and miRabel for differential expression of miRNAs, and Kaplan-Meier for survival prediction. We found that 5.4% of glioblastomas harbored <em>IDH1</em> mutations, correlating with improved overall survival (OS) (<em>p</em> = 2.196e-3). Different glioblastoma cohorts showed a diverse <em>IDH1</em> mutational prevalence (4-31%). Despite this, <em>IDH1</em>^Mu was consistently associated with better OS (<em>p</em> = 8.235e-5). Notably, <em>PDCD1</em> and <em>CD274</em> were statistically significantly highly expressed in both <em>IDH1</em>^Wt (<em>p</em> &lt; 0.0001) and <em>IDH1</em>^Mu tumors (<em>p</em> &lt; 0.0001), with higher expression linked to poorer survival outcomes (<em>PDCD1: p</em> = 0.009; <em>CD274: p</em> = 0.02). Differential co-expression analyses revealed distinct gene and miRNA profiles for <em>IDH1</em>^Wt and <em>IDH1</em>^Mu glioblastomas, with specific upregulation of <em>PTEN</em> and downregulation of <em>MUC16</em> in <em>IDH1</em>^Wt, and upregulation of <em>PIK3R1</em> in <em>IDH1</em>^Mu. Additionally, <em>PIK3R1</em> and <em>ITGB2</em> emerged as critical druggable targets. Our findings indicate that <em>PDCD1</em> and <em>CD274</em> are highly expressed irrespective of <em>IDH1</em> mutation statuses, suggesting that glioblastomas could benefit from immunotherapy. Moreover, <em>IDH1</em>^Mu glioblastomas may require a combination of PI3K/AKT/mTOR inhibitors and immunotherapy due to <em>PIK3R1</em> overexpression.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101182"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The outcomes of pediatric extracranial malignant germ cell tumors: A decade of experience from a single institution in Southern Vietnam","authors":"An Thi Thanh Dao ,&nbsp;Nhi Thuy To ,&nbsp;Chau Hoan Nguyen ,&nbsp;Khai Dinh Truong ,&nbsp;Tuan Diep Tran ,&nbsp;Soh Shui Yen ,&nbsp;Amos Loh Hong Pheng ,&nbsp;Michelle Hermiston ,&nbsp;Phi Duong Nguyen","doi":"10.1016/j.currproblcancer.2025.101197","DOIUrl":"10.1016/j.currproblcancer.2025.101197","url":null,"abstract":"<div><h3>Background</h3><div>Extracranial malignant germ cell tumors (GCTs) generally exhibit favorable outcomes with contemporary therapeutic approaches. However, the outcomes of pediatric GCTs in Vietnam remain unclear. This study aims to evaluate the clinical features, treatment modalities, and prognostic factors associated with survival outcomes in children with GCTs treated at Children's Hospital Number 2 (CH2) in Ho Chi Minh City, Vietnam.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study involving pediatric patients with GCTs treated at CH2 between January 1, 2011, and July 30, 2019. Data were extracted from medical records and entered into REDCap for analysis using SPSS version 20.0 (IBM Corporation, Armonk, NY). Descriptive statistics were reported as mean ± standard deviation, unless otherwise specified. Overall survival (OS) and event-free survival (EFS) rates were estimated using the Kaplan-Meier method, and the log-rank test was employed to assess the significance of potential prognostic factors.</div></div><div><h3>Results</h3><div>A total of 69 patients with a median age of 25 months were included in the study. Of these, 48 (69.9 %) had gonadal tumors, and 21 (30.4 %) had extragonadal tumors. The median alpha-fetoprotein (AFP) level at diagnosis was 2,589 kU/L, with 26 (37.7 %) patients presenting with AFP levels exceeding 10,000 kU/L. All patients underwent surgical resection followed by platinum-based chemotherapy (carboplatin in 92.8 % and cisplatin in 7.2 %). The incidence of grade 3-4 toxicities (neutropenia, febrile neutropenia, and thrombocytopenia) varied between 3.5 % and 19.4 % per chemotherapy cycle. The mean follow-up duration was 53.3 months, with a relapse rate of 5.8 % and an abandonment rate of 11.6 %. The 5-year OS and EFS rates were 92.5 % and 91 %, respectively. EFS was significantly higher in patients with gonadal tumors compared to those with extragonadal tumors (95.7 % vs 84.4 %, <em>p</em> = 0.035). Additionally, OS was significantly better in patients with stage I-II tumors compared to those with stage III-IV (100 % vs 86.2 %, <em>p</em> = 0.03), in patients with AFP levels &lt;10,000 kU/L compared to those with AFP &gt;10,000 kU/L (97.6 % vs 84 %, <em>p</em> = 0.041), and in patients who did not abandon treatment (94.9 % vs 77 %, <em>p</em> = 0.044).</div></div><div><h3>Conclusions</h3><div>The outcomes of pediatric extracranial malignant germ cell tumors in this cohort were excellent, with relatively low early treatment-related toxicity. Reducing treatment abandonment and identifying high-risk patients for intensified therapy may further improve survival outcomes in this setting.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101197"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal age at first birth and uterine cancer risk: A comprehensive analysis using NHANES data (2003–2018)","authors":"Shelby Marozoff ,&nbsp;Mohammad Ehsanul Karim ,&nbsp;Michael Asamoah-Boaheng ,&nbsp;Trevor J.B. Dummer","doi":"10.1016/j.currproblcancer.2025.101184","DOIUrl":"10.1016/j.currproblcancer.2025.101184","url":null,"abstract":"<div><h3>Background</h3><div>Several reproductive factors, including parity and age at menarche, have been identified as risk factors for uterine cancers. However, the association between maternal age at first birth and uterine cancer remains conflicting.</div></div><div><h3>Methods</h3><div>This cross-sectional study included females aged 20 years and older with at least one live birth across eight National Health and Nutrition Examination Survey (NHANES) cycles (2003–2018). We used design-adjusted logistic regression, with multiple imputation for missing data, to explore the association of age at first birth and uterine cancer. As a sensitivity analysis, the sample was restricted to post-menopausal females; logistic regression analyses were repeated.</div></div><div><h3>Results</h3><div>Among 7095 participants, 104 had uterine cancer. The adjusted odds ratio (aOR) for uterine cancer for participants with a first live birth at ≥25 years was 0.66 (95 % confidence interval (CI): 0.33–1.35) compared to those with a first birth at &lt;20 years. For participants with a first birth between 20–24 years, the aOR was 0.93 (95 % CI: 0.51–1.69). Multiple imputation and sensitivity analyses yielded similar non-significant results.</div></div><div><h3>Conclusion</h3><div>Our findings suggest no statistically significant association between maternal age at first live birth and uterine cancer, aligning with existing literature. Further research is needed to explore other reproductive factors and their role in uterine cancer risk.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101184"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy and toxicity of chemotherapeutic regimens used as adjuvant and/or neoadjuvant chemotherapy in penile cancer patients","authors":"Usman Dhasthakeer ,&nbsp;Ambika Nand Jha ,&nbsp;Ashok Kumar Gupta","doi":"10.1016/j.currproblcancer.2025.101185","DOIUrl":"10.1016/j.currproblcancer.2025.101185","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the efficacy and toxicity of different chemotherapeutic regimens used as adjuvant or neoadjuvant chemotherapy in penile cancer patients.</div></div><div><h3>Methodology</h3><div>This observational study was carried out at Mahavir Cancer Sansthan &amp; Research Centre (MCSRC), Patna, involving 112 patients who received various chemotherapy regimens: 5-Fluorouracil with Cisplatin (FP), Paclitaxel with Carboplatin (TP₁), Paclitaxel with Cisplatin (TP₂), and Paclitaxel with Ifosfamide and Cisplatin (TIP). Efficacy was assessed based on tumor response after Neoadjuvant Chemotherapy (NACT) using RECIST v1.1, and Disease-Free Survival (DFS) was calculated with the Kaplan-Meier method. Chemotherapy toxicity was evaluated using CTCAE v4.03, and statistical analysis was performed with SPSS v22.</div></div><div><h3>Results</h3><div>The mean age of the penile cancer patients was found to be 53.5 years. The most of the patients comes under stage-IIIb (62 patients – 55.4%). Out of 88 FP received patients, 28 were treated with NACT in which 24 had partial response (PR) and 4 had progressive disease (PD). The objective response rate (ORR) for this group was found to be 85.71%. Out of 21 TP₁ received patients, 9 were treated with NACT in which 6 had CR and 3 had PR, therefore ORR was found to be 100%. Only one Patient received TIP as NACT had PR. The median DFS rate was found to be 6 months for ACT and 7 months for NACT in FP chemotherapy, whereas 10 months was found to be for ACT and NACT of TP₁ combinations. The patients received TP₁ combinations, had more than 6 months of DFS rate. The grade I-III haematological toxicity of anaemia, lymphocytopenia and thrombocytopenia was observed more in FP than TP₁ and TP₂ combinations. The grade I-III non-haematological toxicity was showed for all chemotherapy combinations.</div></div><div><h3>Conclusion</h3><div>Overall, the TP₁ regimen stands out as the most effective and well-tolerated chemotherapy regimen for penile cancer, demonstrating both superior survival outcomes and a more favourable toxicity profile compared to the FP regimen.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101185"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0147-0272(25)00015-7","DOIUrl":"10.1016/S0147-0272(25)00015-7","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101188"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thallium-201 single photon emission computed tomography for the differentiation of malignant versus non-malignant intracranial space-occupying lesions in developing countries","authors":"Mark Willy L. Mondia ,&nbsp;Anisah Hayaminnah D. Alonto ,&nbsp;Nicole Girlyn T. Pang ,&nbsp;Francis Manuel L. Resma ,&nbsp;Al Joseph R. Molina ,&nbsp;John Kenneth V. Gacula ,&nbsp;Arnel E. Pauco ,&nbsp;Annabell E. Chua ,&nbsp;Julette Marie F. Batara","doi":"10.1016/j.currproblcancer.2024.101160","DOIUrl":"10.1016/j.currproblcancer.2024.101160","url":null,"abstract":"<div><h3>Background</h3><div>Thallium-201 single-photon emission computed tomography (TI-SPECT) imaging has been used historically to distinguish malignant cerebral neoplasms from infectious etiologies.</div></div><div><h3>Objectives</h3><div>Our study aims to conduct a retrospective study, review existing literature, and perform meta-analysis on the use of TI-SPECT to differentiate malignant from non-malignant nervous system lesions when other advanced imaging modalities are not available, such as in resource-limited setting.</div></div><div><h3>Methods</h3><div>A retrospective study on the use of TI-SPECT in differentiating malignant versus non-malignant nervous system lesions was conducted in two tertiary hospitals in the Philippines.</div><div>A systematic review of relevant studies regarding TI-SPECT for the central nervous system was also done. Meta-analysis was performed to generate pooled sensitivity and specificity.</div></div><div><h3>Results</h3><div>A total of 19 patients from 2 institutions were included in the analysis. Data from Philippine General Hospital showed a sensitivity of 83% (95% CI: 36%, 100%) and a specificity of 100% (95% CI: 16%, 100%), while St. Luke's Medical Center had a sensitivity of 100% (95% CI: 40%, 100%) and specificity of 100% (95% CI: 48%, 100%).</div><div>Thirty-two (32) articles were qualitatively described and 24 datasets were subjected to meta-analysis. Pooled sensitivity and specificity were 89% (95% CI: 81%-94%) and 81% (95% CI: 73%-87%), respectively with an area under the curve (AUC) for diagnostic accuracy of 92%.</div></div><div><h3>Conclusion</h3><div>TI-SPECT imaging may be a potential diagnostic tool to discriminate malignant from non-malignant nervous system lesions when advanced imaging modalities such as PET/ MRI are not available. Due to the heterogeneity of the population in the studies included in both the quantitative and qualitative analyses, further studies are needed to validate these findings.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"54 ","pages":"Article 101160"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(25)00004-2","DOIUrl":"10.1016/S0147-0272(25)00004-2","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"54 ","pages":"Article 101177"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}